US5571186A - Pharmaceutical bone growth-promoting composition and process - Google Patents

Pharmaceutical bone growth-promoting composition and process Download PDF

Info

Publication number: US5571186A
Authority: US; United States
Prior art keywords: bone; tricalcium phosphate; isoflavone; isopropoxy; bone growth
Prior art date: 1993-08-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

US08/282,753

Other languages

English (en)

Inventor

Laszlo Prezmeczky

Gusztav Klenk

Erzsebet Englovszky

Tibor Horvath

Laszlo Miszkiewicz

Gabor Szekacs

Ferenc Levai

Magdolna Vitanyi nee Morvai

Original Assignee

Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-02

Filing date

1994-07-29

Publication date

1996-11-05

1994-07-29 Application filed by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt filed Critical Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt

1994-09-23 Assigned to CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. reassignment CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEVAI, FERENC, VITANYI NEE MORVAI, MAGDOLNA, MISZKIEWICZ, LASZLO, SZEKACS, GABOR, ENGLOVSZKY, ERZSEBET, HORVATH, TIBOR, KLENK, GUZSTAV, PREZMECZKY, LASZLO

1996-11-05 Application granted granted Critical

1996-11-05 Publication of US5571186A publication Critical patent/US5571186A/en

2006-10-30 Assigned to PREZMECKY, LASZLO reassignment PREZMECKY, LASZLO ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT.

2014-07-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 53
239000000203 mixture Substances 0.000 title claims abstract description 12
238000000034 method Methods 0.000 title claims description 8
230000008569 process Effects 0.000 title claims description 4
229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 29
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 29
SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims abstract description 27
229960005431 ipriflavone Drugs 0.000 claims abstract description 26
239000001506 calcium phosphate Substances 0.000 claims abstract description 20
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 20
229940078499 tricalcium phosphate Drugs 0.000 claims abstract description 20
229910000391 tricalcium phosphate Inorganic materials 0.000 claims abstract description 20
235000019731 tricalcium phosphate Nutrition 0.000 claims abstract description 20
230000007547 defect Effects 0.000 claims abstract description 11
239000008187 granular material Substances 0.000 claims description 10
230000002950 deficient Effects 0.000 claims description 4
239000002245 particle Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 abstract description 5
241000282472 Canis lupus familiaris Species 0.000 description 7
210000001519 tissue Anatomy 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 4
238000001574 biopsy Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
206010003694 Atrophy Diseases 0.000 description 2
208000010392 Bone Fractures Diseases 0.000 description 2
208000018084 Bone neoplasm Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000002513 implantation Methods 0.000 description 2
210000001847 jaw Anatomy 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000011164 ossification Effects 0.000 description 2
210000003781 tooth socket Anatomy 0.000 description 2
229910002012 Aerosil® Inorganic materials 0.000 description 1
-1 CEROSR 82) Chemical compound 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000008312 Tooth Loss Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002266 amputation Methods 0.000 description 1
210000004763 bicuspid Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
210000004262 dental pulp cavity Anatomy 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000004373 mandible Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000004261 periodontium Anatomy 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
230000008439 repair process Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000001720 vestibular Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/54—Filling; Sealing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/831—Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
- A61K6/838—Phosphorus compounds, e.g. apatite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

the invention relates to a combination useful for the substitution of bone defects which have pathologically developed or have been artificially established as well as compositions containing these combinations and the process for the preparation thereof.
the bone defect is artificially established by removing the tumor tissue or by a bone fracture.
porous hydroxylapatite e.g. CEROS R 80
tricalcium phosphate e.g. CEROS R 82
the object of this invention is to develop a combination, which is useful: to substitute artificially established bone defects [e.g. oral (dental) surgery, removal of bone tumors, bone fractures or the like]; to accelerate the regenerative process of bone defect-substitution carried out with hydroxylapatite or tricalcium phosphate known in the art; and/or to achieve a new bone adapted to the demand of bone hardness locally suitable.
artificially established bone defects e.g. oral (dental) surgery, removal of bone tumors, bone fractures or the like
hydroxylapatite or tricalcium phosphate known in the art
orally administered 7-isopropoxyisoflavone (generic name: IPRIFLAVONE) can be used for the treatment of osteoporosis.
the present invention relates to a combination useful for substituting bone defects having pathologically developed or being artificially established, which comprises 0 to 99.9% by weight of porous hydroxylapatite and/or tricalcium phosphate and 0.001 to 100% by weight of 7-isopropoxyisoflavone, optionally in the form of discrete granules.
the combination according to the invention contains in a weight ratio of 1:9 to 9:1 hydroxylapatite and/or tricalcium phosphate related to 7-isopropoxyisoflavone.
the combination according to the invention contains the active ingredients as discrete (physically separate) granules, where the suitable weight ratio is adjusted by varying the amounts of the different granules.
the composition contains the active ingredients according to the invention together, the composition can preferably be prepared by applying the required amount of 7-isopropoxyisoflavone onto the surface of the porous hydroxylapatite or tricalcium phosphate in a manner known per se (e.g. by wet granulation).
these granules may contain, if desired, also auxiliaries (additives).
additives are e.g. polyvinylpyrrolidone, Avicel, Aerosil, methylcellulose, (hydroxypropyl)cellulose, (hydroxymethyl)propylcellulose, starch, mannitol or the like.
the bone-deficient region is filled by applying suitable surgical techniques with a combination containing porous hydroxylapatite and/or tricalcium phosphate as well as 7-isopropoxyisoflavone, optionally in the form of discrete granules wetted by blood, serum or plasma-substitutes.
the locally suitable bone hardness can be achieved by varying the weight ratio or the particle size of hydroxylapatite and/or tricalcium phosphate used in relation to 7-isopropoxyisoflavone.
hydroxylapatite and/or tricalcium phosphate related to 7-isopropoxyisoflavone is 1:1 and the particle size of hydroxylapatite and/or tricalcium phosphate is 0.5 to 0.8 mm.
the combination according to the invention can be used for the substitution of the following bone defects.
the bone cavities were established by entering the vestibular bone surface on the right side of the lower jaw-bone of the dogs at the site of the roots of the 4th bicuspid by amputating both roots of this tooth and closing the root-canal of the amputation root-stump by a retrograde root filling well established in human dentistry.
the inlet orifice of the bone cavity was shaped to an elliptic form. Hydroxylapatite and ipriflavone mixed together in a ratio corresponding to the respective group were introduced in the form of discrete granules in such a way that the amount of material soaked by blood reached the bone surface level. The wound of the mucous membrane was tightly closed by a suture of 11 knots on average.
the newly formed bone was relatively hard and uniform but not to the same degree as the one obtained with combinations of hydroxylapatite and ipriflavone. There were more loose tissue regions among the separate ossifying islets.
the consistency of tissues formed in the bone cavity and the connection thereof to the surrounding bone can be characterized as a function of the ratio used as follows.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Oral & Maxillofacial Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Transplantation (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Plastic & Reconstructive Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Materials For Medical Uses (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Dental Preparations (AREA)

US08/282,753 1993-08-02 1994-07-29 Pharmaceutical bone growth-promoting composition and process Expired - Lifetime US5571186A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU2230/93		1993-08-02
HU9302230A HU212932B (en)	1993-08-02	1993-08-02	Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition

Publications (1)

Publication Number	Publication Date
US5571186A true US5571186A (en)	1996-11-05

Family

ID=10983854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
US08/282,753 Expired - Lifetime US5571186A (en)	1993-08-02	1994-07-29	Pharmaceutical bone growth-promoting composition and process

Country Status (14)

Country	Link
US (1)	US5571186A (de)
EP (1)	EP0638321B1 (de)
JP (1)	JP3500190B2 (de)
KR (1)	KR950005313A (de)
CN (1)	CN1208093C (de)
AT (1)	ATE188129T1 (de)
AU (1)	AU686632B2 (de)
CA (1)	CA2129279A1 (de)
DE (1)	DE69422346T2 (de)
DK (1)	DK0638321T3 (de)
ES (1)	ES2142893T3 (de)
HU (1)	HU212932B (de)
LV (1)	LV10580B (de)
NZ (1)	NZ264152A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9446087B2 (en)	2006-10-24	2016-09-20	David W. Krempin	Anti-resorptive and bone building dietary supplements and methods of use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU9502198D0 (en) *	1995-07-21	1995-09-28	Chinoin Gyogyszer Es Vegyeszet	Novel indication

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3949085A (en) *	1970-05-27	1976-04-06	Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt	Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US5110720A (en) *	1987-02-03	1992-05-05	Reanal Einomvegyszergyar	Dental composition and a process for the preparation thereof
US5124325A (en) *	1989-06-13	1992-06-23	Kyorin Pharmaceutical Co., Ltd.	Therapeutic agents of metabolic bone disease
US5164187A (en) *	1990-04-05	1992-11-17	Norian Corporation	Hydroxyapatite prosthesis coatings

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU162377B (de) *	1970-05-27	1973-02-28
JPS59199630A (ja) *	1983-04-26	1984-11-12	Takeda Chem Ind Ltd	卵巣機能低下症治療剤
HU199444B (en) *	1985-09-10	1990-02-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
IT1241079B (it) *	1990-03-23	1993-12-29	Chiesi Farma Spa	Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
IT1244697B (it) *	1991-02-01	1994-08-08	Chiesi Farma Spa	Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale

1993
- 1993-08-02 HU HU9302230A patent/HU212932B/hu active IP Right Revival
1994
- 1994-07-29 LV LVP-94-150A patent/LV10580B/en unknown
- 1994-07-29 AU AU68810/94A patent/AU686632B2/en not_active Ceased
- 1994-07-29 US US08/282,753 patent/US5571186A/en not_active Expired - Lifetime
- 1994-08-01 ES ES94111951T patent/ES2142893T3/es not_active Expired - Lifetime
- 1994-08-01 EP EP94111951A patent/EP0638321B1/de not_active Expired - Lifetime
- 1994-08-01 DE DE69422346T patent/DE69422346T2/de not_active Expired - Fee Related
- 1994-08-01 KR KR1019940019026A patent/KR950005313A/ko not_active Abandoned
- 1994-08-01 DK DK94111951T patent/DK0638321T3/da active
- 1994-08-01 AT AT94111951T patent/ATE188129T1/de not_active IP Right Cessation
- 1994-08-02 CN CNB941161919A patent/CN1208093C/zh not_active Expired - Fee Related
- 1994-08-02 CA CA002129279A patent/CA2129279A1/en not_active Abandoned
- 1994-08-02 NZ NZ264152A patent/NZ264152A/en unknown
- 1994-08-02 JP JP18141294A patent/JP3500190B2/ja not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3949085A (en) *	1970-05-27	1976-04-06	Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt	Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US5110720A (en) *	1987-02-03	1992-05-05	Reanal Einomvegyszergyar	Dental composition and a process for the preparation thereof
US5124325A (en) *	1989-06-13	1992-06-23	Kyorin Pharmaceutical Co., Ltd.	Therapeutic agents of metabolic bone disease
US5164187A (en) *	1990-04-05	1992-11-17	Norian Corporation	Hydroxyapatite prosthesis coatings

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9446087B2 (en)	2006-10-24	2016-09-20	David W. Krempin	Anti-resorptive and bone building dietary supplements and methods of use
US11207368B2 (en)	2006-10-24	2021-12-28	Murray Mary A	Anti-resorptive and bone building dietary supplements and methods of use

Also Published As

Publication number	Publication date
NZ264152A (en)	1996-08-27
AU686632B2 (en)	1998-02-12
EP0638321A1 (de)	1995-02-15
JPH07144018A (ja)	1995-06-06
DE69422346T2 (de)	2000-07-27
EP0638321B1 (de)	1999-12-29
CN1105271A (zh)	1995-07-19
JP3500190B2 (ja)	2004-02-23
LV10580A (lv)	1995-04-20
KR950005313A (ko)	1995-03-20
ES2142893T3 (es)	2000-05-01
HUT71253A (en)	1995-11-28
HU9302230D0 (en)	1993-10-28
AU6881094A (en)	1995-02-09
DK0638321T3 (da)	2000-06-19
CN1208093C (zh)	2005-06-29
LV10580B (en)	1995-10-20
HU212932B (en)	1996-12-30
DE69422346D1 (de)	2000-02-03
CA2129279A1 (en)	1995-02-03
ATE188129T1 (de)	2000-01-15

Legal Events

Date	Code	Title	Description
1994-09-23	AS	Assignment	Owner name: CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PREZMECZKY, LASZLO;KLENK, GUZSTAV;ENGLOVSZKY, ERZSEBET;AND OTHERS;REEL/FRAME:007149/0611;SIGNING DATES FROM 19940905 TO 19940916
1996-11-07	STCF	Information on status: patent grant	Free format text: PATENTED CASE
2000-04-28	FPAY	Fee payment	Year of fee payment: 4
2004-04-28	FPAY	Fee payment	Year of fee payment: 8
2006-10-30	AS	Assignment	Owner name: PREZMECKY, LASZLO, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT.;REEL/FRAME:018454/0442 Effective date: 20061026
2006-12-01	FEPP	Fee payment procedure	Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY
2007-12-05	FEPP	Fee payment procedure	Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY
2008-05-05	FPAY	Fee payment	Year of fee payment: 12

Publication	Publication Date	Title
Rocci et al.	2003	Immediate loading of Brånemark System® TiUnite™ and machined‐surface implants in the posterior mandible: a randomized open‐ended clinical trial
Maiorana et al.	2017	Alveolar socket preservation with demineralised bovine bone mineral and a collagen matrix
Minamizato et al.	2018	Clinical application of autogenous partially demineralized dentin matrix prepared immediately after extraction for alveolar bone regeneration in implant dentistry: a pilot study
Iasella et al.	2003	Ridge preservation with freeze‐dried bone allograft and a collagen membrane compared to extraction alone for implant site development: A clinical and histologic study in humans
Cochran et al.	2000	Evaluation of recombinant human bone morphogenetic protein‐2 in oral applications including the use of endosseous implants: 3‐year results of a pilot study in humans
Schepers et al.	1993	Bioactive glass particles of narrow size range: a new material for the repair of bone defects
Karabuda et al.	2001	Histological and clinical evaluation of 3 different grafting materials for sinus lifting procedure based on 8 cases
Yilmaz et al.	1998	Alveolar ridge reconstruction and/or preservation using root form bioglass cones
Zucchelli et al.	2003	Enamel matrix protines bovine porous bone mineral in the treatment of intrabony defects: Comparative controlled clinical trial
Kenney et al.	1985	The use of a porous hydroxylapatite implant in periodontal defects: I. Clinical results after six months
Hartwell et al.	1993	Healing of furcation perforations in primate teeth after repair with decalcified freeze-dried bone: a longitudinal study
Nemcovsky et al.	2000	Rotated palatal flap in immediate implant procedures: clinical evaluation of 26 consecutive cases
De Wijs et al.	1994	Front tooth replacement with Tübingen (Frialit®) implants
Parodi et al.	2000	Use of Emdogain in the treatment of deep intrabony defects: 12-month clinical results. Histologic and radiographic evaluation.
Alhadainy et al.	1998	Use of a hydroxylapatite-based material and calcium sulfate as artificial floors to repair furcal perforations
Cangini et al.	2005	A comparison between enamel matrix derivative and a bioabsorbable membrane to enhance healing around transmucosal immediate post‐extraction implants
RU2181576C1 (ru)	2002-04-27	Способ ранней дентальной имплантации
Rossmeisl et al.	1982	A study of freeze-dried (lyophilized) cortical bone used as an apical barrier in adult monkey teeth
US5571186A (en)	1996-11-05	Pharmaceutical bone growth-promoting composition and process
Nemcovsky et al.	2019	Modern clinical procedures in periodontal reconstructive treatment
Zucchelli	2007	Long-term maintenance of an apparently hopeless tooth: a case report.
Hammad et al.	2021	Immediate implant placement with immediate provisionalization in the maxillary esthetic zone using mixture of allograft and xenograft vs xenografts to augment the jumping gap (A Randomized Clinical Trial)
Mattout et al.	1984	Juvenile periodontitis: healing following autogenous iliac marrow graft, long‐term evaluation
Lei et al.	2024	Seven-Year Esthetic and Radiographic Stability of Anterior Maxillary Implants after DBBM–Collagen Matrix Ridge Preservation
Matijević et al.	2019	THE USE OF INJECTABLE BIPHASIC CALCIUM PHOSPHATE IN GUIDED BONE REGENERATION